filmov
tv
ASCO 2024 and ESMO GI 2024 Updates Webinar | Feat. Dr. Samuel Klempner
Показать описание
Join Debbie's Dream Foundation for an insightful webinar with Dr. Samuel Klempner, a leading expert in gastroesophageal oncology from Massachusetts General Hospital and Harvard Medical School.
Dr. Klempner will discuss the latest updates from the ASCO 2024 conference, covering breakthrough research and new therapies in cancer care. He will also share key findings from the ESMO GI 2024 conference held in Munich, Germany. Tune in to gain valuable insights and learn about cutting-edge advancements in gastric and esophageal cancer treatment.
Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI esophagogastric task force, and is on the NCCN guideline committees for gastric and esophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and esophageal cancer outreach and patient advocacy.
Dr. Klempner will discuss the latest updates from the ASCO 2024 conference, covering breakthrough research and new therapies in cancer care. He will also share key findings from the ESMO GI 2024 conference held in Munich, Germany. Tune in to gain valuable insights and learn about cutting-edge advancements in gastric and esophageal cancer treatment.
Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and esophageal program. His clinical and translational research is centered on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI esophagogastric task force, and is on the NCCN guideline committees for gastric and esophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and esophageal cancer outreach and patient advocacy.